<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00232180</url>
  </required_header>
  <id_info>
    <org_study_id>A6141079</org_study_id>
    <nct_id>NCT00232180</nct_id>
  </id_info>
  <brief_title>A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines</brief_title>
  <acronym>EMPHASIS-HF</acronym>
  <official_title>The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In an earlier study, eplerenone was shown to improve survival in patients who had heart
      failure immediately following a heart attack. However, it is not known how patients with
      established mild-to-moderate heart failure (NYHA Class II), who have the additional risk of
      sudden death, will respond if treated with eplerenone. In this trial, eplerenone plus
      standard heart failure medicines is being compared to placebo plus standard heart failure
      medicines in terms of an additional ability to prolong life and prevent re-hospitalizations
      for worsening heart failure in these patients.

      The Data Safety Monitoring Committee (DSMC) observed during its conduct of the
      protocol-specified second interim analysis on the 6th of May, 2010 that the efficacy of
      eplerenone had met the pre-specified stopping rules in the protocol. As a result of the
      discussion between the DSMC and the Executive Steering Committee (ESC), the ESC recommended
      that EMPHASIS-HF should be terminated, Based on the convincing efficacy and the consideration
      that it would be unethical not to offer this treatment to patients, the ESC recommended that
      all the patients in the trial should be transferred to open-label eplerenone. The Open Label
      Extension eplerenone arm will last for 12 months. Eplerenone is not currently approved for
      the indication studied in this patient population.

      On May 26, 2010, further enrollment into EMPHASIS-HF was stopped. The amendment is considered
      to be the most appropriate way to ensure that all the subjects who participated in the
      double-blind phase of the EMPHASIS-HF trial can be offered treatment with eplerenone
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off Date</measure>
    <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010)</time_frame>
    <description>CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated)</measure>
    <time_frame>Baseline (30 March 2006) up to 59.5 months (complete DB phase: 18 March 2011)</time_frame>
    <description>CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Occurrence of All-Cause Mortality or Heart Failure (HF) Hospitalization (Adjudicated)</measure>
    <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
    <description>Death due to any cause or first of occurrence HF hospitalization. HF hospitalization is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Occurrence of All-Cause Mortality (Adjudicated)</measure>
    <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
    <description>Death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Occurrence of Cardiovascular (CV) Mortality (Adjudicated)</measure>
    <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
    <description>CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Occurrence of All-Cause Hospitalization (Adjudicated)</measure>
    <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
    <description>Hospitalization due to any cause is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Occurrence of Heart Failure (HF) Hospitalization (Adjudicated)</measure>
    <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
    <description>First occurrence of HF hospitalization. Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Occurrence of All-Cause Mortality or All-Cause Hospitalization (Adjudicated)</measure>
    <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
    <description>Death due to any cause or hospitalization due to any cause. Hospitalization due to any cause is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Occurrence Of Heart Failure (HF) Mortality or Heart Failure (HF) Hospitalization (Adjudicated)</measure>
    <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
    <description>Death due to HF or first occurrence of HF hospitalization. Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Occurrence of Cardiovascular (CV) Hospitalization (Adjudicated)</measure>
    <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
    <description>First occurrence of CV hospitalization. CV hospitalization is defined as hospitalization due to HF (first or subsequent), acute myocardial infarction, angina pectoris (unstable), cardiac arrhythmia (atrial fibrillation [AF], atrial flutter, supraventricular arrhythmias, or ventricular arrhythmias), stroke/CVA, other CV reasons (such as hypotension or peripheral vascular disease), implantation of a cardioverter defibrillator (ICD), or cardiac resynchronization therapy (CRT) with CV event as the primary reason for hospitalization as determined by endpoint committee adjudicator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Occurrence of Fatal or Non-fatal Myocardial Infarction (Adjudicated)</measure>
    <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Occurrence of Fatal or Non-fatal Stroke (Adjudicated)</measure>
    <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Occurrence of Implantation of Cardiac Defibrillator (ICD) (Adjudicated)</measure>
    <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
    <description>First occurrence of implantation of cardiac defibrillator (ICD). ICD is an electronic device capable of monitoring the heart rhythm. When the heart is beating normally, the device remains inactive. If the heart develops a life-threatening tachycardia, the ICD delivers electrical shocks to the heart to terminate the abnormal rhythm and return the heart rhythm to normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Occurrence of Implantation of Resynchronization Device (Cardiac Resynchronization Therapy [CRT]) (Adjudicated)</measure>
    <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
    <description>First occurrence of implantation of resynchronization device. CRT is use of a specialized pacemaker to re-coordinate the action of the right and left ventricles in heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Occurrence of Hospitalization Due to Worsening Renal Function (Adjudicated)</measure>
    <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
    <description>First occurrence of hospitalization due to worsening renal function. Hospitalization due to worsening renal function is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to worsening renal function as the primary reason for hospitalization as determined by endpoint committee adjudicator. Worsening renal function is defined as doubling of serum creatinine level from baseline level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Occurrence of Hospitalization Due to Hyperkalemia (Adjudicated)</measure>
    <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
    <description>First occurrence of hospitalization due to hyperkalemia. Hospitalization due to hyperkalemia is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to hyperkalemia as the primary reason for hospitalization as determined by endpoint committee adjudicator. Hyperkalemia is defined as serum potassium level greater than (&gt;) 5.5 milliequivalents per liter (mEq/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New Onset Atrial Fibrillation or Flutter</measure>
    <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
    <description>New onset of atrial fibrillation or flutter is defined as the diagnosis of atrial fibrillation or flutter in a participant after randomization, where atrial fibrillation was not present before randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New Onset Diabetes Mellitus (DM)</measure>
    <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
    <description>The definition of new onset diabetes mellitus is the diagnosis of diabetes mellitus in a participant after randomization, when DM was not present before randomization.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2743</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Eplerenone arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eplerenone administered on top of background standard heart failure therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>Eplerenone administered on top of background standard heart failure therapy</description>
    <arm_group_label>Eplerenone arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History (Hx) of chronic systolic heart failure of ischemic or non-ischemic etiology of
             at least 4 weeks duration; Currently, New York Heart Association (NYHA) functional
             Class II and on optimal dose, or maximally tolerated dose of standard heart failure
             medicines (advisable to include ACE-I/ARBs; beta-blockers) and diuretics if indicated
             for fluid overload. Should have participated in the double-blind phase of the
             EMPHASIS-HF trial

        Exclusion Criteria:

          -  Severe chronic systolic heart failure symptomatic at rest despite optimal medical
             therapy; estimated glomerular filtration rate (eGFR) &lt;30 ml/min/1.73m2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Merced</city>
        <state>California</state>
        <zip>95340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40205-3374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044-2914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>MN</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tupeelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801-4600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>New Hampshire</state>
        <zip>03102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leetsdale</city>
        <state>Pennsylvania</state>
        <zip>15056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cumberland</city>
        <state>Rhode Island</state>
        <zip>02864</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37917</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231-7906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moron</city>
        <state>Pcia. de Buenos Aires</state>
        <zip>1708</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1428</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5003DCE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Launceston</city>
        <state>Tasmania</state>
        <zip>7250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Antwerpen</city>
        <zip>B-2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bonheiden</city>
        <zip>B-2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Eupen</city>
        <zip>B-4700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Huy</city>
        <zip>B-4500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>La Louvière</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lanaken</city>
        <zip>3620</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Overpelt</city>
        <zip>B-3900</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St-Charles Borromee</city>
        <state>Quebec</state>
        <zip>J6E 6J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St-georges (Beauce)</city>
        <state>Quebec</state>
        <zip>G5Y 4T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Plzen</city>
        <zip>30599</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Plzen</city>
        <zip>323 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 1</city>
        <zip>110 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 1</city>
        <zip>118 33</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 6</city>
        <zip>169 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pribram</city>
        <zip>261 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <state>Cedex 4</state>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Creteil</city>
        <state>Cedex</state>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gap</city>
        <state>Cedex</state>
        <zip>05000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Angers Cedex 01</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cergy-Pontoise</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chateauroux</city>
        <zip>36019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gap CEDEX</city>
        <zip>05007</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nantes Cedex 01</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nice CEDEX 1</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nîmes</city>
        <zip>30000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paris CEDEX 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St-Amand-Montrond</city>
        <zip>18206</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bad Rothenfelde</city>
        <zip>49214</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12621</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12683</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Duisburg</city>
        <zip>47137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60594</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hagen</city>
        <zip>58095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Halle</city>
        <zip>06110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66424</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Koeln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Athens</city>
        <state>Attika</state>
        <zip>16672</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Haidari</city>
        <state>Attiki</state>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>10671</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>14388</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chai Wan</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pokfulam</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shatin NT</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>H-1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mosonmagyarovar</city>
        <zip>9200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Siófok</city>
        <zip>8601</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Szeged</city>
        <zip>H-6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500 034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pune</city>
        <state>Maharshtra</state>
        <zip>411 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ludhiana</city>
        <state>Punjab</state>
        <zip>141 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>400 037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <zip>641 014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226 014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>Co.</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bergamo (BG)</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mestre - Zelardino (ve)</city>
        <zip>30164</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Palermo</city>
        <zip>90100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Piacenza</city>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Trieste</city>
        <zip>30147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Venezia</city>
        <zip>30122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Republic of Korea</city>
        <state>Korea</state>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Suwon</city>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Aguascalientes</city>
        <state>Aguacalientes</state>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>02720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chihuahua</city>
        <zip>31238</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78210</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <zip>5211 NL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Apeldoorn</city>
        <zip>7314 ET</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Apeldoorn</city>
        <zip>7334 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Arnhem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Deventer</city>
        <zip>7416 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dordrecht</city>
        <zip>3317 NM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dordrecht</city>
        <zip>3318 AT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Veldhoven</city>
        <zip>5504 DB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Velp</city>
        <zip>6883 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zwolle</city>
        <zip>8011 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Piotrkow Trybunalski</city>
        <zip>97-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-834</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Stalowa Wola</city>
        <zip>37-450</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Szczecin</city>
        <zip>71-455</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>03-242</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Guilhufe - PNF</city>
        <state>Penafiel</state>
        <zip>4560-162</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Almada</city>
        <zip>2801-951</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amadora</city>
        <zip>2700-276</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Linda-a-Velha</city>
        <zip>2799-523</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1499-005</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1769-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oliveira de Azemeis</city>
        <zip>3720-275</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Portalegre</city>
        <zip>7301-853</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vila Franca de Xira</city>
        <zip>2600-178</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vila Real</city>
        <zip>5000</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>113093</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>S-Petersburg</city>
        <zip>192104</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>S-Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>196084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Voronezh</city>
        <zip>394053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>168752</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>811 05</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>813 69</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>831 03</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>833 03</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>833 48</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Levice</city>
        <zip>934 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Liptovsky Mikulas</city>
        <zip>031 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Trencin</city>
        <zip>911 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Soweto</city>
        <state>Johannesburg</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9300</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7405</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Congella</city>
        <zip>4013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kwazulu Natal</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Barakaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Almeria</city>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Angelholm</city>
        <zip>262 81</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bollnas</city>
        <zip>821 34</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Falun</city>
        <zip>791 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Goteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Goteborg</city>
        <zip>416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Halmstad</city>
        <zip>301 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hässleholm</city>
        <zip>281 31</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lindesberg</city>
        <zip>711 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Linkoping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lulea</city>
        <zip>971 80</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Molndal</city>
        <zip>431 80</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Skelleftea</city>
        <zip>S-931 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Varberg</city>
        <zip>432 41</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vaxjo</city>
        <zip>351 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Simferopol</city>
        <state>Crimea</state>
        <zip>95026</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49060</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Donetsk</city>
        <zip>83003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Donetsk</city>
        <zip>83114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kiev</city>
        <zip>03151</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>02125</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lviv</city>
        <zip>79013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lviv</city>
        <zip>79015</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Odessa</city>
        <zip>65009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Odessa</city>
        <zip>65039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Uzhgorod</city>
        <zip>88014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69118</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dubai</city>
        <state>UAE</state>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Abu Dhabi</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Knutsford</city>
        <state>Cheshire</state>
        <zip>WA16 0BT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Macclesfield</city>
        <state>Cheshire</state>
        <zip>SK10 3BL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <state>Strathclyde</state>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Coventry</city>
        <zip>CVZ 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 8TA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Larbert</city>
        <zip>FK5 4WR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Macclesfield</city>
        <zip>SK10 3BL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Milton Keynes</city>
        <zip>MK6 5LD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Southend-on-Sea</city>
        <zip>SS0 0RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Torquay</city>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Caracas</city>
        <state>Distrito Capital</state>
        <zip>1061</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Caracas</city>
        <state>Estado Miranda</state>
        <zip>1060</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Caracas</city>
        <state>Estado Miranda</state>
        <zip>1061</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United Arab Emirates</country>
    <country>United Kingdom</country>
    <country>United States</country>
    <country>Venezuela</country>
  </location_countries>
  <removed_countries>
    <country>Egypt</country>
    <country>Jordan</country>
    <country>Lebanon</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6141079&amp;StudyName=A%20Comparison%20Of%20Outcomes%20In%20Patients%20In%20New%20York%20Heart%20Association%20%28NYHA%29%20Class%20II%20Heart%20Failure%20When%20Treated%20With%20Eplerenone%20Or</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2005</study_first_submitted>
  <study_first_submitted_qc>September 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2005</study_first_posted>
  <results_first_submitted>May 20, 2011</results_first_submitted>
  <results_first_submitted_qc>May 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 27, 2011</results_first_posted>
  <last_update_submitted>March 28, 2013</last_update_submitted>
  <last_update_submitted_qc>March 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open-label</keyword>
  <keyword>single arm mortality/morbidity trial eplerenone chronic systolic heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 1597 participants who completed the double-blind phase, 1246 entered into the open-label phase and 351 participants were ineligible to participate the open-label phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Eplerenone: Double-blind Phase</title>
          <description>Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heart failure therapy. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an estimated glomerular filtration rate (eGFR) between 30 to 49 milliliter per minute divided by 1.73 squared meter (ml/min/1.73m^2), initial dose was 25 mg orally once every other day; at Week 4, dose might have been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
        </group>
        <group group_id="P2">
          <title>Placebo: Double-blind Phase</title>
          <description>Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.</description>
        </group>
        <group group_id="P3">
          <title>Eplerenone: Open Label Phase</title>
          <description>Participants from double blind phase received eplerenone 25 mg tablet orally once daily on top of standard heart failure therapy for 12 months. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an eGFR between 30 to 49 ml/min/1.73m^2 in the double blind phase, initial dose was 25 mg orally once every other day; at Week 4, dose might had been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind (DB) Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1367">Three participants in each arm were enrolled after data cut-off.</participants>
                <participants group_id="P2" count="1376">Three participants in each arm were enrolled after data cut-off.</participants>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="1364"/>
                <participants group_id="P2" count="1372"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="826"/>
                <participants group_id="P2" count="771"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="541"/>
                <participants group_id="P2" count="605"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="186"/>
                <participants group_id="P2" count="222"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="148"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Laboratory abnormality</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open Label Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1246"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1245"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1098"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="148"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Laboratory abnormality</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Eplerenone</title>
          <description>Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heart failure therapy. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an estimated glomerular filtration rate (eGFR) between 30 to 49 milliliter per minute divided by 1.73 squared meter (ml/min/1.73m^2), initial dose was 25 mg orally once every other day; at Week 4, dose might have been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1367"/>
            <count group_id="B2" value="1376"/>
            <count group_id="B3" value="2743"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than (&lt;) 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="443"/>
                    <measurement group_id="B2" value="441"/>
                    <measurement group_id="B3" value="884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 to 74 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="594"/>
                    <measurement group_id="B2" value="607"/>
                    <measurement group_id="B3" value="1201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>75 to 84 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="302"/>
                    <measurement group_id="B2" value="299"/>
                    <measurement group_id="B3" value="601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than or equal to (&gt;=) 85 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="309"/>
                    <measurement group_id="B2" value="302"/>
                    <measurement group_id="B3" value="611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1058"/>
                    <measurement group_id="B2" value="1074"/>
                    <measurement group_id="B3" value="2132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off Date</title>
        <description>CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator.</description>
        <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010)</time_frame>
        <population>Full analysis set (FAS) using intent-to-treat (ITT) principle: All randomized participants, followed for mortality, other major endpoints for duration of double blind treatment period, regardless of compliance with study drug and protocol. Here 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone: Double-blind Phase</title>
            <description>Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heart failure therapy. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an estimated glomerular filtration rate (eGFR) between 30 to 49 milliliter per minute divided by 1.73 squared meter (ml/min/1.73m^2), initial dose was 25 mg orally once every other day; at Week 4, dose might have been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Double-blind Phase</title>
            <description>Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off Date</title>
          <description>CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator.</description>
          <population>Full analysis set (FAS) using intent-to-treat (ITT) principle: All randomized participants, followed for mortality, other major endpoints for duration of double blind treatment period, regardless of compliance with study drug and protocol. Here 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1364"/>
                <count group_id="O2" value="1373"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249"/>
                    <measurement group_id="O2" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cox proportional hazard model includes treatment as the major factor, adjusting for age, estimated glomerular filtration rate, left ventricular ejection fraction, body mass index, hemoglobin, heart rate, systolic blood pressure, diabetes, history of hypertension, prior myocardial infarction, baseline left bundle branch block, time from electrocardiogram Q wave to the end of the S wave corresponding to ventricle depolarization (QRS) and atrial fibrillation as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Using an adaptation of Haybittle-Peto stopping criterion adjusting for two interim analyses, p-value for final primary analysis will be compared to alpha=0.049. No adjustment in alpha will be made on parameters/endpoints other than primary endpoint.</p_value_desc>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.630</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.535</ci_lower_limit>
            <ci_upper_limit>0.741</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated)</title>
        <description>CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator.</description>
        <time_frame>Baseline (30 March 2006) up to 59.5 months (complete DB phase: 18 March 2011)</time_frame>
        <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone: Double-blind Phase</title>
            <description>Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heart failure therapy. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an estimated glomerular filtration rate (eGFR) between 30 to 49 milliliter per minute divided by 1.73 squared meter (ml/min/1.73m^2), initial dose was 25 mg orally once every other day; at Week 4, dose might have been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Double-blind Phase</title>
            <description>Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated)</title>
          <description>CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator.</description>
          <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1367"/>
                <count group_id="O2" value="1376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288"/>
                    <measurement group_id="O2" value="392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Occurrence of All-Cause Mortality or Heart Failure (HF) Hospitalization (Adjudicated)</title>
        <description>Death due to any cause or first of occurrence HF hospitalization. HF hospitalization is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator.</description>
        <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
        <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone: Double-blind Phase</title>
            <description>Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heart failure therapy. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an estimated glomerular filtration rate (eGFR) between 30 to 49 milliliter per minute divided by 1.73 squared meter (ml/min/1.73m^2), initial dose was 25 mg orally once every other day; at Week 4, dose might have been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Double-blind Phase</title>
            <description>Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of All-Cause Mortality or Heart Failure (HF) Hospitalization (Adjudicated)</title>
          <description>Death due to any cause or first of occurrence HF hospitalization. HF hospitalization is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator.</description>
          <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1367"/>
                <count group_id="O2" value="1376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to 50 months (cut-off) (n= 1364, 1373)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270"/>
                    <measurement group_id="O2" value="376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 59.5 months (complete DB) (n= 1367, 1376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311"/>
                    <measurement group_id="O2" value="418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis was only performed on the adjudicated endpoint data up to cut-off. Cox proportional hazard model includes treatment as the major factor, adjusting for age, estimated glomerular filtration rate, left ventricular ejection fraction, body mass index, hemoglobin, heart rate, systolic blood pressure, diabetes, history of hypertension, prior myocardial infarction, baseline left bundle branch block, QRS complex and atrial fibrillation as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistically significant if p-value &lt;0.01</p_value_desc>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.647</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.552</ci_lower_limit>
            <ci_upper_limit>0.757</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Occurrence of All-Cause Mortality (Adjudicated)</title>
        <description>Death due to any cause.</description>
        <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
        <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone: Double-blind Phase</title>
            <description>Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heart failure therapy. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an estimated glomerular filtration rate (eGFR) between 30 to 49 milliliter per minute divided by 1.73 squared meter (ml/min/1.73m^2), initial dose was 25 mg orally once every other day; at Week 4, dose might have been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Double-blind Phase</title>
            <description>Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of All-Cause Mortality (Adjudicated)</title>
          <description>Death due to any cause.</description>
          <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1367"/>
                <count group_id="O2" value="1376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to 50 months (cut-off) (n= 1364, 1373)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 59.5 months (complete DB) (n= 1367, 1376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis was only performed on the adjudicated endpoint data up to cut-off. Cox proportional hazard model includes treatment as the major factor, adjusting for age, estimated glomerular filtration rate, left ventricular ejection fraction, body mass index, hemoglobin, heart rate, systolic blood pressure, diabetes, history of hypertension, prior myocardial infarction, baseline left bundle branch block, QRS complex and atrial fibrillation as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0081</p_value>
            <p_value_desc>Statistically significant if p-value &lt;0.01</p_value_desc>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.761</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.622</ci_lower_limit>
            <ci_upper_limit>0.932</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Occurrence of Cardiovascular (CV) Mortality (Adjudicated)</title>
        <description>CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism).</description>
        <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
        <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone: Double-blind Phase</title>
            <description>Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heart failure therapy. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an estimated glomerular filtration rate (eGFR) between 30 to 49 milliliter per minute divided by 1.73 squared meter (ml/min/1.73m^2), initial dose was 25 mg orally once every other day; at Week 4, dose might have been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Double-blind Phase</title>
            <description>Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of Cardiovascular (CV) Mortality (Adjudicated)</title>
          <description>CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism).</description>
          <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1367"/>
                <count group_id="O2" value="1376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to 50 months (cut-off) (n= 1364, 1373)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 59.5 months (complete DB) (n= 1367, 1376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis was only performed on the adjudicated endpoint data up to cut-off. Cox proportional hazard model includes treatment as the major factor, adjusting for age, estimated glomerular filtration rate, left ventricular ejection fraction, body mass index, hemoglobin, heart rate, systolic blood pressure, diabetes, history of hypertension, prior myocardial infarction, baseline left bundle branch block, QRS complex and atrial fibrillation as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0120</p_value>
            <p_value_desc>Statistically significant if p-value &lt;0.01</p_value_desc>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.757</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.609</ci_lower_limit>
            <ci_upper_limit>0.941</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Occurrence of All-Cause Hospitalization (Adjudicated)</title>
        <description>Hospitalization due to any cause is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility).</description>
        <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
        <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone: Double-blind Phase</title>
            <description>Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heart failure therapy. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an estimated glomerular filtration rate (eGFR) between 30 to 49 milliliter per minute divided by 1.73 squared meter (ml/min/1.73m^2), initial dose was 25 mg orally once every other day; at Week 4, dose might have been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Double-blind Phase</title>
            <description>Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of All-Cause Hospitalization (Adjudicated)</title>
          <description>Hospitalization due to any cause is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility).</description>
          <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1367"/>
                <count group_id="O2" value="1376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to 50 months (cut-off) (n= 1364, 1373)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="408"/>
                    <measurement group_id="O2" value="491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 59.5 months (complete DB) (n= 1367, 1376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="463"/>
                    <measurement group_id="O2" value="552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis was only performed on the adjudicated endpoint data up to cut-off. Cox proportional hazard model includes treatment as the major factor, adjusting for age, estimated glomerular filtration rate, left ventricular ejection fraction, body mass index, hemoglobin, heart rate, systolic blood pressure, diabetes, history of hypertension, prior myocardial infarction, baseline left bundle branch block, QRS complex and atrial fibrillation as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistically significant if p-value &lt;0.01</p_value_desc>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.768</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.673</ci_lower_limit>
            <ci_upper_limit>0.876</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Occurrence of Heart Failure (HF) Hospitalization (Adjudicated)</title>
        <description>First occurrence of HF hospitalization. Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator.</description>
        <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
        <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone: Double-blind Phase</title>
            <description>Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heart failure therapy. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an estimated glomerular filtration rate (eGFR) between 30 to 49 milliliter per minute divided by 1.73 squared meter (ml/min/1.73m^2), initial dose was 25 mg orally once every other day; at Week 4, dose might have been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Double-blind Phase</title>
            <description>Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of Heart Failure (HF) Hospitalization (Adjudicated)</title>
          <description>First occurrence of HF hospitalization. Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator.</description>
          <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1367"/>
                <count group_id="O2" value="1376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to 50 months (cut-off) (n= 1364, 1373)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                    <measurement group_id="O2" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 59.5 months (complete DB) (n= 1367, 1376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                    <measurement group_id="O2" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis was only performed on the adjudicated endpoint data up to cut-off. Cox proportional hazard model includes treatment as the major factor, adjusting for age, estimated glomerular filtration rate, left ventricular ejection fraction, body mass index, hemoglobin, heart rate, systolic blood pressure, diabetes, history of hypertension, prior myocardial infarction, baseline left bundle branch block, QRS complex and atrial fibrillation as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistically significant if p-value &lt;0.01</p_value_desc>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.576</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.473</ci_lower_limit>
            <ci_upper_limit>0.702</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Occurrence of All-Cause Mortality or All-Cause Hospitalization (Adjudicated)</title>
        <description>Death due to any cause or hospitalization due to any cause. Hospitalization due to any cause is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility).</description>
        <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
        <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone: Double-blind Phase</title>
            <description>Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heart failure therapy. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an estimated glomerular filtration rate (eGFR) between 30 to 49 milliliter per minute divided by 1.73 squared meter (ml/min/1.73m^2), initial dose was 25 mg orally once every other day; at Week 4, dose might have been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Double-blind Phase</title>
            <description>Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of All-Cause Mortality or All-Cause Hospitalization (Adjudicated)</title>
          <description>Death due to any cause or hospitalization due to any cause. Hospitalization due to any cause is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility).</description>
          <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1367"/>
                <count group_id="O2" value="1376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to 50 months (cut-off) (n= 1364, 1373)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="462"/>
                    <measurement group_id="O2" value="569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 59.5 months (complete DB) (n= 1367, 1376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="530"/>
                    <measurement group_id="O2" value="636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis was only performed on the adjudicated endpoint data up to cut-off. Cox proportional hazard model includes treatment as the major factor, adjusting for age, estimated glomerular filtration rate, left ventricular ejection fraction, body mass index, hemoglobin, heart rate, systolic blood pressure, diabetes, history of hypertension, prior myocardial infarction, baseline left bundle branch block, QRS complex and atrial fibrillation as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistically significant if p-value &lt;0.01</p_value_desc>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.751</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.664</ci_lower_limit>
            <ci_upper_limit>0.849</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Occurrence Of Heart Failure (HF) Mortality or Heart Failure (HF) Hospitalization (Adjudicated)</title>
        <description>Death due to HF or first occurrence of HF hospitalization. Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator.</description>
        <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
        <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone: Double-blind Phase</title>
            <description>Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heart failure therapy. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an estimated glomerular filtration rate (eGFR) between 30 to 49 milliliter per minute divided by 1.73 squared meter (ml/min/1.73m^2), initial dose was 25 mg orally once every other day; at Week 4, dose might have been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Double-blind Phase</title>
            <description>Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence Of Heart Failure (HF) Mortality or Heart Failure (HF) Hospitalization (Adjudicated)</title>
          <description>Death due to HF or first occurrence of HF hospitalization. Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator.</description>
          <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1367"/>
                <count group_id="O2" value="1376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to 50 months (cut-off) (n= 1364, 1373)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 59.5 months (complete DB) (n= 1367, 1376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194"/>
                    <measurement group_id="O2" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis was only performed on the adjudicated endpoint data up to cut-off. Cox proportional hazard model includes treatment as the major factor, adjusting for age, estimated glomerular filtration rate, left ventricular ejection fraction, body mass index, hemoglobin, heart rate, systolic blood pressure, diabetes, history of hypertension, prior myocardial infarction, baseline left bundle branch block, QRS complex and atrial fibrillation as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistically significant if p-value &lt;0.01</p_value_desc>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.577</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.475</ci_lower_limit>
            <ci_upper_limit>0.701</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Occurrence of Cardiovascular (CV) Hospitalization (Adjudicated)</title>
        <description>First occurrence of CV hospitalization. CV hospitalization is defined as hospitalization due to HF (first or subsequent), acute myocardial infarction, angina pectoris (unstable), cardiac arrhythmia (atrial fibrillation [AF], atrial flutter, supraventricular arrhythmias, or ventricular arrhythmias), stroke/CVA, other CV reasons (such as hypotension or peripheral vascular disease), implantation of a cardioverter defibrillator (ICD), or cardiac resynchronization therapy (CRT) with CV event as the primary reason for hospitalization as determined by endpoint committee adjudicator.</description>
        <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
        <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone: Double-blind Phase</title>
            <description>Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heart failure therapy. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an estimated glomerular filtration rate (eGFR) between 30 to 49 milliliter per minute divided by 1.73 squared meter (ml/min/1.73m^2), initial dose was 25 mg orally once every other day; at Week 4, dose might have been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Double-blind Phase</title>
            <description>Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of Cardiovascular (CV) Hospitalization (Adjudicated)</title>
          <description>First occurrence of CV hospitalization. CV hospitalization is defined as hospitalization due to HF (first or subsequent), acute myocardial infarction, angina pectoris (unstable), cardiac arrhythmia (atrial fibrillation [AF], atrial flutter, supraventricular arrhythmias, or ventricular arrhythmias), stroke/CVA, other CV reasons (such as hypotension or peripheral vascular disease), implantation of a cardioverter defibrillator (ICD), or cardiac resynchronization therapy (CRT) with CV event as the primary reason for hospitalization as determined by endpoint committee adjudicator.</description>
          <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1367"/>
                <count group_id="O2" value="1376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to 50 months (cut-off) (n= 1364, 1373)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304"/>
                    <measurement group_id="O2" value="399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 59.5 months (complete DB) (n= 1367, 1376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="346"/>
                    <measurement group_id="O2" value="439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis was only performed on the adjudicated endpoint data up to cut-off. Cox proportional hazard model includes treatment as the major factor, adjusting for age, estimated glomerular filtration rate, left ventricular ejection fraction, body mass index, hemoglobin, heart rate, systolic blood pressure, diabetes, history of hypertension, prior myocardial infarction, baseline left bundle branch block, QRS complex and atrial fibrillation as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistically significant if p-value &lt;0.01</p_value_desc>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.694</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.598</ci_lower_limit>
            <ci_upper_limit>0.806</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Occurrence of Fatal or Non-fatal Myocardial Infarction (Adjudicated)</title>
        <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
        <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone: Double-blind Phase</title>
            <description>Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heart failure therapy. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an estimated glomerular filtration rate (eGFR) between 30 to 49 milliliter per minute divided by 1.73 squared meter (ml/min/1.73m^2), initial dose was 25 mg orally once every other day; at Week 4, dose might have been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Double-blind Phase</title>
            <description>Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of Fatal or Non-fatal Myocardial Infarction (Adjudicated)</title>
          <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1367"/>
                <count group_id="O2" value="1376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to 50 months (cut-off) (n= 1364, 1373)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 59.5 months (complete DB) (n= 1367, 1376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis was only performed on the adjudicated endpoint data up to cut-off. Cox proportional hazard model includes treatment as the major factor, adjusting for age, estimated glomerular filtration rate, left ventricular ejection fraction, body mass index, hemoglobin, heart rate, systolic blood pressure, diabetes, history of hypertension, prior myocardial infarction, baseline left bundle branch block, QRS complex and atrial fibrillation as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2321</p_value>
            <p_value_desc>Statistically significant if p-value &lt;0.01</p_value_desc>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.316</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.839</ci_lower_limit>
            <ci_upper_limit>2.064</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Occurrence of Fatal or Non-fatal Stroke (Adjudicated)</title>
        <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
        <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone: Double-blind Phase</title>
            <description>Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heart failure therapy. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an estimated glomerular filtration rate (eGFR) between 30 to 49 milliliter per minute divided by 1.73 squared meter (ml/min/1.73m^2), initial dose was 25 mg orally once every other day; at Week 4, dose might have been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Double-blind Phase</title>
            <description>Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of Fatal or Non-fatal Stroke (Adjudicated)</title>
          <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1367"/>
                <count group_id="O2" value="1376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to 50 months (cut-off) (n= 1364, 1373)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 59.5 months (complete DB) (n= 1367, 1376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis was only performed on the adjudicated endpoint data up to cut-off. Cox proportional hazard model includes treatment as the major factor, adjusting for age, estimated glomerular filtration rate, left ventricular ejection fraction, body mass index, hemoglobin, heart rate, systolic blood pressure, diabetes, history of hypertension, prior myocardial infarction, baseline left bundle branch block, QRS complex and atrial fibrillation as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4213</p_value>
            <p_value_desc>Statistically significant if p-value &lt;0.01</p_value_desc>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.789</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.443</ci_lower_limit>
            <ci_upper_limit>1.406</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Occurrence of Implantation of Cardiac Defibrillator (ICD) (Adjudicated)</title>
        <description>First occurrence of implantation of cardiac defibrillator (ICD). ICD is an electronic device capable of monitoring the heart rhythm. When the heart is beating normally, the device remains inactive. If the heart develops a life-threatening tachycardia, the ICD delivers electrical shocks to the heart to terminate the abnormal rhythm and return the heart rhythm to normal.</description>
        <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
        <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone: Double-blind Phase</title>
            <description>Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heart failure therapy. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an estimated glomerular filtration rate (eGFR) between 30 to 49 milliliter per minute divided by 1.73 squared meter (ml/min/1.73m^2), initial dose was 25 mg orally once every other day; at Week 4, dose might have been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Double-blind Phase</title>
            <description>Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of Implantation of Cardiac Defibrillator (ICD) (Adjudicated)</title>
          <description>First occurrence of implantation of cardiac defibrillator (ICD). ICD is an electronic device capable of monitoring the heart rhythm. When the heart is beating normally, the device remains inactive. If the heart develops a life-threatening tachycardia, the ICD delivers electrical shocks to the heart to terminate the abnormal rhythm and return the heart rhythm to normal.</description>
          <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1367"/>
                <count group_id="O2" value="1376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to 50 months (cut-off) (n= 1364, 1373)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 59.5 months (complete DB) (n= 1367, 1376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis was only performed on the adjudicated endpoint data up to cut-off. Cox proportional hazard model includes treatment as the major factor, adjusting for age, estimated glomerular filtration rate, left ventricular ejection fraction, body mass index, hemoglobin, heart rate, systolic blood pressure, diabetes, history of hypertension, prior myocardial infarction, baseline left bundle branch block, QRS complex and atrial fibrillation as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9754</p_value>
            <p_value_desc>Statistically significant if p-value &lt;0.01</p_value_desc>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.994</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.694</ci_lower_limit>
            <ci_upper_limit>1.424</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Occurrence of Implantation of Resynchronization Device (Cardiac Resynchronization Therapy [CRT]) (Adjudicated)</title>
        <description>First occurrence of implantation of resynchronization device. CRT is use of a specialized pacemaker to re-coordinate the action of the right and left ventricles in heart failure.</description>
        <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
        <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone: Double-blind Phase</title>
            <description>Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heart failure therapy. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an estimated glomerular filtration rate (eGFR) between 30 to 49 milliliter per minute divided by 1.73 squared meter (ml/min/1.73m^2), initial dose was 25 mg orally once every other day; at Week 4, dose might have been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Double-blind Phase</title>
            <description>Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of Implantation of Resynchronization Device (Cardiac Resynchronization Therapy [CRT]) (Adjudicated)</title>
          <description>First occurrence of implantation of resynchronization device. CRT is use of a specialized pacemaker to re-coordinate the action of the right and left ventricles in heart failure.</description>
          <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1367"/>
                <count group_id="O2" value="1376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to 50 months (cut-off) (n= 1364, 1373)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 59.5 months (complete DB) (n= 1367, 1376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis was only performed on the adjudicated endpoint data up to cut-off. Cox proportional hazard model includes treatment as the major factor, adjusting for age, estimated glomerular filtration rate, left ventricular ejection fraction, body mass index, hemoglobin, heart rate, systolic blood pressure, diabetes, history of hypertension, prior myocardial infarction, baseline left bundle branch block, QRS complex and atrial fibrillation as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2652</p_value>
            <p_value_desc>Statistically significant if p-value &lt;0.01</p_value_desc>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.770</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.485</ci_lower_limit>
            <ci_upper_limit>1.220</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Occurrence of Hospitalization Due to Worsening Renal Function (Adjudicated)</title>
        <description>First occurrence of hospitalization due to worsening renal function. Hospitalization due to worsening renal function is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to worsening renal function as the primary reason for hospitalization as determined by endpoint committee adjudicator. Worsening renal function is defined as doubling of serum creatinine level from baseline level.</description>
        <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
        <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone: Double-blind Phase</title>
            <description>Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heart failure therapy. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an estimated glomerular filtration rate (eGFR) between 30 to 49 milliliter per minute divided by 1.73 squared meter (ml/min/1.73m^2), initial dose was 25 mg orally once every other day; at Week 4, dose might have been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Double-blind Phase</title>
            <description>Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of Hospitalization Due to Worsening Renal Function (Adjudicated)</title>
          <description>First occurrence of hospitalization due to worsening renal function. Hospitalization due to worsening renal function is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to worsening renal function as the primary reason for hospitalization as determined by endpoint committee adjudicator. Worsening renal function is defined as doubling of serum creatinine level from baseline level.</description>
          <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1367"/>
                <count group_id="O2" value="1376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to 50 months (cut-off) (n= 1364, 1373)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 59.5 months (complete DB) (n= 1367, 1376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis was only performed on the adjudicated endpoint data up to cut-off. Cox proportional hazard model includes treatment as the major factor, adjusting for age, estimated glomerular filtration rate, left ventricular ejection fraction, body mass index, hemoglobin, heart rate, systolic blood pressure, diabetes, history of hypertension, prior myocardial infarction, baseline left bundle branch block, QRS complex and atrial fibrillation as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9537</p_value>
            <p_value_desc>Statistically significant if p-value &lt;0.01</p_value_desc>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.971</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.366</ci_lower_limit>
            <ci_upper_limit>2.578</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Occurrence of Hospitalization Due to Hyperkalemia (Adjudicated)</title>
        <description>First occurrence of hospitalization due to hyperkalemia. Hospitalization due to hyperkalemia is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to hyperkalemia as the primary reason for hospitalization as determined by endpoint committee adjudicator. Hyperkalemia is defined as serum potassium level greater than (&gt;) 5.5 milliequivalents per liter (mEq/L).</description>
        <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
        <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone: Double-blind Phase</title>
            <description>Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heart failure therapy. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an estimated glomerular filtration rate (eGFR) between 30 to 49 milliliter per minute divided by 1.73 squared meter (ml/min/1.73m^2), initial dose was 25 mg orally once every other day; at Week 4, dose might have been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Double-blind Phase</title>
            <description>Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of Hospitalization Due to Hyperkalemia (Adjudicated)</title>
          <description>First occurrence of hospitalization due to hyperkalemia. Hospitalization due to hyperkalemia is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to hyperkalemia as the primary reason for hospitalization as determined by endpoint committee adjudicator. Hyperkalemia is defined as serum potassium level greater than (&gt;) 5.5 milliequivalents per liter (mEq/L).</description>
          <population>FAS using ITT principle: All randomized participants, followed for mortality and other major endpoints for the duration of the double blind treatment period, regardless of compliance with the study drug and the protocol. Here “n” signifies participants evaluated at that time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1367"/>
                <count group_id="O2" value="1376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to 50 months (cut-off) (n= 1364, 1373)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 59.5 months (complete DB) (n= 1367, 1376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis was only performed on the adjudicated endpoint data up to cut-off. Cox proportional hazard model includes treatment as the major factor, adjusting for age, estimated glomerular filtration rate, left ventricular ejection fraction, body mass index, hemoglobin, heart rate, systolic blood pressure, diabetes, history of hypertension, prior myocardial infarction, baseline left bundle branch block, QRS complex and atrial fibrillation as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8539</p_value>
            <p_value_desc>Statistically significant if p-value &lt;0.01</p_value_desc>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.154</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.251</ci_lower_limit>
            <ci_upper_limit>5.312</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New Onset Atrial Fibrillation or Flutter</title>
        <description>New onset of atrial fibrillation or flutter is defined as the diagnosis of atrial fibrillation or flutter in a participant after randomization, where atrial fibrillation was not present before randomization.</description>
        <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
        <population>FAS using ITT principle: Here 'N' (Number of Participants Analyzed) signifies those who did not report a history of atrial fibrillation at baseline and “n” signifies participants evaluated at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone: Double-blind Phase</title>
            <description>Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heart failure therapy. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an estimated glomerular filtration rate (eGFR) between 30 to 49 milliliter per minute divided by 1.73 squared meter (ml/min/1.73m^2), initial dose was 25 mg orally once every other day; at Week 4, dose might have been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Double-blind Phase</title>
            <description>Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New Onset Atrial Fibrillation or Flutter</title>
          <description>New onset of atrial fibrillation or flutter is defined as the diagnosis of atrial fibrillation or flutter in a participant after randomization, where atrial fibrillation was not present before randomization.</description>
          <population>FAS using ITT principle: Here 'N' (Number of Participants Analyzed) signifies those who did not report a history of atrial fibrillation at baseline and “n” signifies participants evaluated at that time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="956"/>
                <count group_id="O2" value="940"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to 50 months (cut-off) (n= 950, 937)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 59.5 months (complete DB) (n= 956, 940)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis was only performed on the adjudicated endpoint data up to cut-off. Cox proportional hazard model includes treatment as the major factor, adjusting for age, estimated glomerular filtration rate, left ventricular ejection fraction, body mass index, hemoglobin, heart rate, systolic blood pressure, diabetes, history of hypertension, prior myocardial infarction, baseline left bundle branch block, QRS complex and atrial fibrillation as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0175</p_value>
            <p_value_desc>Statistically significant if p-value &lt;0.01</p_value_desc>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.585</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.376</ci_lower_limit>
            <ci_upper_limit>0.910</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New Onset Diabetes Mellitus (DM)</title>
        <description>The definition of new onset diabetes mellitus is the diagnosis of diabetes mellitus in a participant after randomization, when DM was not present before randomization.</description>
        <time_frame>Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)</time_frame>
        <population>FAS using ITT principle: Here 'N' (Number of Participants Analyzed) signifies those who did not report a history of diabetes mellitus at baseline and “n” signifies participants evaluated at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone: Double-blind Phase</title>
            <description>Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heart failure therapy. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an estimated glomerular filtration rate (eGFR) between 30 to 49 milliliter per minute divided by 1.73 squared meter (ml/min/1.73m^2), initial dose was 25 mg orally once every other day; at Week 4, dose might have been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Double-blind Phase</title>
            <description>Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New Onset Diabetes Mellitus (DM)</title>
          <description>The definition of new onset diabetes mellitus is the diagnosis of diabetes mellitus in a participant after randomization, when DM was not present before randomization.</description>
          <population>FAS using ITT principle: Here 'N' (Number of Participants Analyzed) signifies those who did not report a history of diabetes mellitus at baseline and “n” signifies participants evaluated at that time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="907"/>
                <count group_id="O2" value="975"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to 50 months (cut-off) (n= 904, 973)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 59.5 months (complete DB) (n= 907, 975)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis was only performed on the adjudicated endpoint data up to cut-off. Cox proportional hazard model includes treatment as the major factor, adjusting for age, estimated glomerular filtration rate, left ventricular ejection fraction, body mass index, hemoglobin, heart rate, systolic blood pressure, diabetes, history of hypertension, prior myocardial infarction, baseline left bundle branch block, QRS complex and atrial fibrillation as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6009</p_value>
            <p_value_desc>Statistically significant if p-value &lt;0.01</p_value_desc>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.885</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.559</ci_lower_limit>
            <ci_upper_limit>1.400</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. The numbers of subjects with each AE or SAE are summarized. If a subject had multiple episodes of the same AE or SAE during the study, only the most severe case of the AE or SAE for the subject are summarized.</desc>
      <group_list>
        <group group_id="E1">
          <title>Eplerenone: Double-blind Phase (May 25, 2010 Data Cut-off)</title>
          <description>Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heart failure therapy. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an estimated glomerular filtration rate (eGFR) between 30 to 49 milliliter per minute divided by 1.73 squared meter (ml/min/1.73m^2), initial dose was 25 mg orally once every other day; at Week 4, dose might have been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
        </group>
        <group group_id="E2">
          <title>Placebo: Double-blind Phase(May 25, 2010 Data Cutoff)</title>
          <description>Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.</description>
        </group>
        <group group_id="E3">
          <title>Eplerenone: Double-blind Phase</title>
          <description>Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heartfailure therapy. Dose might have been increased at Week 4 to 50 mg once daily.For participants with an estimated glomerular filtration rate (eGFR) between 30 to49 milliliter per minute divided by 1.73 squared meter (ml/min/1.73m^2), initialdose was 25 mg orally once every other day; at Week 4, dose might have beenincreased to a maximum of 25 mg once daily based on serum potassium level.</description>
        </group>
        <group group_id="E4">
          <title>Placebo: Double-blind Phase</title>
          <description>Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.</description>
        </group>
        <group group_id="E5">
          <title>Eplerenone: Open Label Phase</title>
          <description>Participants from double blind phase received eplerenone 25 mg tablet orally once daily on top of standard heart failure therapy for 12 months. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an eGFR between 30 to 49 ml/min/1.73m^2 in the double blind phase, initial dose was 25 mg orally once every other day; at Week 4, dose might had been increased to a maximum of 25 mg once daily based on serum potassium level.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="509" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="614" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="586" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="686" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="251" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Heparin-induced thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hilar lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy mediastinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardiac aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="187" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="243" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="218" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="270" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="44" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardiac perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Low cardiac output syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Mitral valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Supraventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Ventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Haematotympanum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Thyroid disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis fugax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Phacolytic glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Abdominal hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Crohn’s disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pancreatolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Proctitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Mesenteric occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pancreatic insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Crepitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Device lead damage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Device pacing issue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Device stimulation issue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Implant site discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Lipogranuloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hepatorenal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Dermo-hypodermitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hepatobiliary infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Implant site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Infected dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Joint tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Phlebitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Herpes zoster ophthalmic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Joint abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Tuberculous laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Infected sebaceous cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Bone fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Haematuria traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Lip injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Postoperative hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Radiation skin injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Mouth injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arteriogram</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Arthroscopy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Blood glucose abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Carotid bruit</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>International normalised ratio decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Colposcopy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Endoscopy upper gastrointestinal tract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Podagra</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Dupuytren’s contracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Rheumatic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Spondyloarthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Sympathetic posterior cervical syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Axillary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Adenoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Adrenal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Benign laryngeal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Biliary neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Bronchial neoplasm benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of ampulla of Vater</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of pleura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Myelofibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Neoplasm prostate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pituitary tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Rectal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Vulval cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Chronic myelomonocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Brain neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pleura carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Carotid artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cerebral atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hemianopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Spinal cord disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Spinal cord ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hypoxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pseudodementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Schizophrenia, paranoid type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Somatoform disorder cardiovascular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Panic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardiac neurosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Haemorrhage urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Brain hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Bronchial disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cheyne-Stokes respiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Diaphragmatic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Dyspnoea at rest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Mediastinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pleural disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pleural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Vocal cord disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Nasal turbinate hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hydropneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Bladder operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardiac ablation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker replacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker revision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardiac resynchronisation therapy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardiovascular event prophylaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardioversion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cervical conisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Colectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Foot amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Gallbladder operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Heart transplan</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator insertion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Lipoma excision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Lung lobectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Lung neoplasm surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Medical device implantation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Mitral valve repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Mitral valve replacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Prophylaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Renal transplant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Therapeutic procedure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Thrombolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Vascular operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Aortic valve replacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hip surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator replacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Arterial disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Arterial insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Arteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Femoral artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis obliterans</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="547" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="540" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="640" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="617" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="329" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="107" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="66" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="101" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="62" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="43" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="43" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 15.1">Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1245"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.1">Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1360"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="1369"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="1364"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="1372"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="1245"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

